The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

BACKGROUND: Glioblastoma (GBM) is a fatal brain tumor, lacking effective treatment. Epidermal growth factor receptor (EGFR) is recognized as an attractive target for GBM treatment. However, GBMs have very poor responses to the first- and second-generation EGFR inhibitors. The third-generation EGFR-t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Exp Clin Cancer Res
Päätekijät: Liu, Xuejiao, Chen, Xiangyu, Shi, Lin, Shan, Qianqian, Cao, Qiyu, Yue, Chenglong, Li, Huan, Li, Shengsheng, Wang, Jie, Gao, Shangfeng, Niu, Mingshan, Yu, Rutong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6533774/
https://ncbi.nlm.nih.gov/pubmed/31122294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1235-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia